A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

Journal of Neurology

Volumn 260, Issue 4, 2013, Pages 984-997

  Langford, R M ^a   Mares, J ^b   Novotna, A ^c   Vachova, M ^d   Novakova, I ^e   Notcutt, W ^f   Ratcliffe, S ^g  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c Pardubice Regional Hospital   (Czech Republic)

^d Nefakultni Regionalni Centrum   (Czech Republic)

^e MS Centrum Karlovo namesti   (Czech Republic)

^f JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

^g MAC Clinical Research Cobra Court   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoid; Central neuropathic pain; Delta 9 tetrahydrocannabinol; Multiple sclerosis; THC CBD oromucosal spray

Indexed keywords

NABIXIMOLS; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP QUALITY; TIME TO TREATMENT; TREATMENT FAILURE; WITHDRAWAL SYNDROME;

ADMINISTRATION, MUCOSAL; ADMINISTRATION, ORAL; ADULT; ANALGESICS, NON-NARCOTIC; ANALYSIS OF VARIANCE; CANNABIDIOL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEURALGIA; PAIN MEASUREMENT; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 84876488583     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6739-4     Document Type: Article

References (28)

1. Richards RG, Sampson FC, Beard SM, Tappenden P (2006) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6(10):1-73
2. Fox CM, Bensa S, Bray I, Zajicek JP (2004) The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria. J Neurol Neurosurg Psychiatry 75:56-60
3. Merskey H, Bogduk N (1994) Classification of chronic pain. IASP Press, Seattle, pp 1-222
4. Clifford DB, Trotter JL (1984) Pain in multiple sclerosis. Arch Neurol 41:1270-1272
5. Vermote R, Ketelaer P, Carton H (1986) Pain in multiple sclerosis patients. Clin Neurol Neurosurg 88:87-93
6. Moulin DE, Foley KM, Ebers GC (1988) Pain syndromes in multiple sclerosis. Neurology 38:1830-1834
7. Stenager E, Knudsen L, Jensen K (1991) Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 84:197-200
8. Bonica JJ (1991) Introduction Semantic, Epidemiologic, and Educational Issues. In: Casey KL (ed) Pain and Central Nervous System Disease The Central Pain Syndromes. Raven Press, Ltd. New York 21
9. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS et al (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132(3):237-251
10. Saarto T, Wiffen P. Antidepressants for neuropathic pain (2005) The Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD005454
11. Wiffen PJ, McQuay HJ, Moore RA (2005) Carbamazepine for acute and chronic pain. The Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD005451
12. Zajicek P, Apostu VI (2011) Role of cannabinoids in multiple sclerosis. CNS Drugs 25(8):187-201
13. Cheng Y, Hitchcock SA (2007) Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs 16(7):951-965
14. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161-202
15. Pertwee RG (2007) Cannabinoids and multiple sclerosis. Mol Neurobiol 36:45-59
16. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermannson NO, Leonova J et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:984-986
17. Pertwee R (2001) Cannabinoid receptors and pain. Prog Neuro-biol 63:569-611
18. Begg M, Dale N, Llaudet E, Molleman A (2002) Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum. Br J Pharmacol 137(8):1298-1304
19. MHRA Public Assessment Report. Nabiximols Oromucosal Spray (delta-9-tetrahydrocannabinol and cannabidiol) - PL 18024/0009; UK/H/2462/001/DC http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con084961.pdf (2010, accessed November 2011)
20. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized controlled trial of cannabis based medicine in central pain due to multiple sclerosis. Neurology 65:812-819
21. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta-9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29(9):2068-2079
22. Iskedjian M, Brezza B, Gordon A, Piwko C, Einarson TR (2007) Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 23(1):17-24
23. Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 299:306
24. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised double-blind, placebo-controlled clinical trial. Pain 133:210-220
25. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6(4):253-260
26. Selvarajah D, Gandhi R, Witte D, Bowler H, Emery C, Tesfaye S (2006) Treatment of painful diabetic neuropathy with Nabiximols (a cannabis-based medicinal product) - results of a randomised placebo controlled trial. Diabetologia 49(Suppl 1):671-672
27. The Committee For Medicinal Products For Human Use (CHMP) Guideline On Clinical Investigation Of Medicinal Products Intended For The Treatment Of Neuropathic Pain, London, 18 November 2004 CHMP/EWP/252/03
28. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V (2008) Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 135(3):217-220